title: [Diagnosis and Treatment of HBOC Syndrome by a Breast Surgical Oncologist].
abstract: Of all breast cancer cases, 5-10% occur because of inherited germline mutation. For hereditary breast and ovarian cancer (HBOC)syndrome, congenital knowledge and strategies for breast cancer treatment and risk reduction are necessary. Regarding the surgical procedure for the cancer site, the ipsilateral breast tumor recurrence rate following breast-conserving surgery in breast cancers with BRCA1/2 mutation is not significantly higher than that in sporadic breast cancers. In addition, prognosis did not differ according to surgical methods. Therefore, breast-conserving surgery for HBOC is not an absolute contraindication, although the risk of developing new primary tumors in the long term should be carefully considered. For the contralateral breast, 3 choices are available, surveillance, chemo-prevention, and risk-reducing mastectomy. Risk-reducing mastectomy is known to decrease the risk of breast cancer by 90%. Genetic counseling is essential for decision making in HBOC treatment. In this review, we reevaluated the current evidence for surgical decision making and systemic therapies for HBOC syndrome.
authors.affiliation: Dept. of Breast Surgical Oncology, St. Luke's International Hospital.
authors.forename: Kumiko
authors.initials: K
authors.lastname: Kida
authors.forename: Michiko
authors.initials: M
authors.lastname: Murai
authors.forename: Hideko
authors.initials: H
authors.lastname: Yamauchi
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use; D019313:BRCA1 Protein / Q000235:genetics; D024682:BRCA2 Protein / Q000235:genetics; D005260:Female; D061325:Hereditary Breast and Ovarian Cancer Syndrome / Q000175:diagnosis / Q000188:drug therapy* / Q000235:genetics / Q000601:surgery*; D006801:Humans; D012307:Risk Factors
chemical_list: D000970:Antineoplastic Agents; D019313:BRCA1 Protein; C492913:BRCA1 protein, human; D024682:BRCA2 Protein; C551750:BRCA2 protein, human